Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:10/26/2007

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 14 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 23,600 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. Sonic Foundry reports GAAP loss as Q2 revenues rise
4. Fiserv reports $113.5 million in Q1 profit
5. Third Wave reports net loss of $18.9M for 2006
6. Musicnotes reports 45 percent growth in 2006
7. Sonic Foundry reports net loss, higher revenue
8. Sonic Foundry reports first cash-positive quarter
9. Merge Healthcare reports $10.8M net loss in Q3
10. Third Wave reports $5.2M third quarter loss
11. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... creating professional commercial video content, to analysis of athletic performance. Producing high-resolution ... go by too quickly to process with the naked eye. , Slow ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
...   ReportsnReports announces it will carry , ... Browse the complete , , Daptomycin ... Search 75000+ Market Research,Reports Browse ... Report Summary Eliminate unnecessary risk with the industry benchmark in,comprehensive ...
... 27, 2011 MedeAnalytics, a leading provider of ... of its Patient Access Resource Center. Created in ... of the revenue cycle, the resource center provides ... industry trends, as well as best-practice tools and ...
... The pharmaceutical industry spent less on drug R&D last year ... data released today from the 2011 Pharmaceutical R&D ... Key highlights from the 2011 R&D ... were launched on the global market in 2010, a decrease from ...
Cached Biology Technology:ReportsnReports - Daptomycin - Comprehensive Patent Search 2ReportsnReports - Daptomycin - Comprehensive Patent Search 3ReportsnReports - Daptomycin - Comprehensive Patent Search 4ReportsnReports - Daptomycin - Comprehensive Patent Search 5Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International 2Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International 3
(Date:8/11/2015)... Sweden , August 11, 2015 Today, ... FPC1155. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
(Date:8/6/2015)... and TELTOW, Germany , ... 2015 Siggraph Conference, SensoMotoric Instruments (SMI) shows ... reality , based on Epson,s Moverio BT-200 ... tracking platform. With this new solution, unprecedented quality and ... hands-free interaction with context-sensitive displays. For the first time, ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... Two Fortune 500 oil companies have committed major ... University of Houston. The funds, from energy industry leaders ... support for a new undergraduate program in petroleum engineering, ... Higher Education Coordinating Board this fall. "Marathon,s and ...
... can be genotypic (GSD) or temperature-dependent (TSD). TSD is ... sensitive periods of early development irreversibly determines whether an ... males and females in a population is the sex ... A number of previous studies have also suggested ...
... cell technology are among the cutting-edge approaches to ... Fox Foundation,s Rapid Response Innovation Awards 2008. As ... and a cure for PD, the Foundation has ... disease research projects under the initiative in the ...
Cached Biology News:Energy industry leaders commit $1.6M to UH petroleum program 2Energy industry leaders commit $1.6M to UH petroleum program 3Fish with temperature-dependent sex determination face global warming 2Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinson's Disease 2Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinson's Disease 3
... a fully automated microplate based multi-detection ... in academia and industry. The FLUOstar ... Fluorescence Intensity including FRET and ... including DELFIATM High-Performance Luminescence (flash ...
... can operate as a Voltage Clamp, as a ... in electrophysiology research applications. Performance in any one ... • This amazing instrument ... the capabilities of Digital Signal Processing (DSP) integrated ...
... activity is expressed in g per ml and ... saline, pH 6.8, of a 1 mg per ... lowest concentration to agglutinate a 2% suspension of ... incubation at 25 C. Preparation Note: ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
Biology Products: